

10000389

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1613sxw

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

10000389

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:38:46 ON 22 JUL 2003

FILE 'REGISTRY' ENTERED AT 13:38:54 ON 22 JUL 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2003 HIGHEST RN 552272-14-7  
DICTIONARY FILE UPDATES: 21 JUL 2003 HIGHEST RN 552272-14-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

```
=>  
Uploading 10000389c.str
```

## L1 STRUCTURE UPLOADED

=> d  
L1 HAS NO ANSWERS  
L1 STR

10000389



G1 H, Ak

G2 C, O, S, N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:39:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED      14 ITERATIONS          4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:  56 TO      504
PROJECTED ANSWERS:     4 TO       200
```

L2 4 SEA SSS SAM L1

```
=> s l1 full
FULL SEARCH INITIATED 13:39:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 254 TO ITERATE

100.0% PROCESSED      254 ITERATIONS         69 ANSWERS
SEARCH TIME: 00.00.01
```

L3 69 SEA SSS FUL L1

```
=> fil caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST      SINCE FILE ENTRY      TOTAL SESSION
                           148.15           148.36
```

10000389

FILE 'CAPLUS' ENTERED AT 13:39:19 ON 22 JUL 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jul 2003 VOL 139 ISS 4  
FILE LAST UPDATED: 21 Jul 2003 (20030721/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 13 full  
L4 4 L3

=> d 14 1-4 ibib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2003:15497 CAPLUS  
DOCUMENT NUMBER: 138:78430  
TITLE: Pharmaceutical compositions containing heterocyclic compounds as .alpha.1.beta.2 integrin-mediated adhesion inhibitors for treatment of inflammatory diseases  
INVENTOR(S): Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall; Smith, Nicholas; Griffith, Ronald C.  
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003002834	A2	20030108	JP 2002-117406	20020419
PRIORITY APPLN. INFO.:			JP 2001-121235	A 20010419
OTHER SOURCE(S):	MARPAT	138:78430		
GI				

10000389



AB Title compns., useful for treatment of asthma, thrombosis, arteriosclerosis, osteoporosis, tumor, rheumatoid arthritis, etc., contain heterocyclic compds. I [A = :CZ1, :N; B = CR1R2, CH:CH, S, SO, SO2, O, NR3, NR3CO, etc.; K = CH2, CHO, CO, CF2, M = bond, (CH2)p, CO, NH, W = :Q, CHR1C:Q, C:QCHR6; X, Y = H, halo, NO2, CN, C1-6 alkylthio, (un)substituted aryl, etc.; Z, Z1 = H, OH, halo, NO2, CF3, C1-6 alkoxy carbonyl, etc.; P, Q = O, S; R = (un)substituted (hetero)aryl; R1, R2 = H, halo, OR3, NR3R6, O2CNR32, N3, (un)substituted aryl, etc.; R1R2 may be linked to form O, etc.; R3 = H, (un)substituted C1-6 alkyl, (un)substituted (hetero)aryl, etc.; R6 = H, (un)substituted C1-6 alkyl; m = 0-3; n = 0-2, o, p = 1, 2] or their pharmacol. acceptable salts as active ingredients. Thus, (5R,7S)-5-[4-(trifluoromethoxy)benzyl]-3-(2,6-dichloro-4-pyridyl)-7-acetamido-1,3-diazabicyclo[3.3.0]octane-2,4-dione inhibited adhesion of Jurkat cell to ICAM-1 with IC50 value of 0.005 .mu.M.

IT 336812-89-6P 336812-90-9P 336812-91-0P  
336812-92-1P 336812-93-2P 336816-67-2P  
336816-69-4P 336816-73-0P 336816-77-4P  
336816-81-0P 336817-14-2P 336817-20-0P  
481704-12-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic compds. as .alpha.1.beta.2 integrin-mediated adhesion inhibitors for treatment of inflammatory diseases)

RN 336812-89-6 CAPLUS

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10000389

RN 336812-90-9 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-91-0 CAPLUS

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-92-1 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336812-93-2 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-67-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-73-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-oxo-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-77-4 CAPLUS

CN 1-Piperazinebutanamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-methyl-.gamma.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-81-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336817-14-2 CAPLUS

CN Morpholine, 4-[(6R,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336817-20-0 CAPLUS

CN Morpholine, 4-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 481704-12-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-[(6-methyl-3-pyridinyl)carbonyl]-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:428909 CAPLUS

DOCUMENT NUMBER: 137:6181

TITLE: Preparation of fused hydantoins as antiinflammatories.

INVENTOR(S): Iwanowicz, Edwin J.; Dhar, Murali T. G.; Launay, Michele; Potin, Dominique; Maillet, Magali Jeannine Blandine; Nicolai, Eric Antoine

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; CEREP SA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

10000389

WO 2002044181 A1 20020606 WO 2001-US45540 20011130  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,  
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
AU 200227128200 A5 20020611 AU 2002-27128 20011130  
US 2002143035 A1 20021003 US 2001-389 20011130  
PRIORITY APPLN. INFO.: US 2000-250486P P 20001201  
US 2000-250653P P 20001201  
US 2001-272165P P 20010228  
WO 2001-US45540 W 20011130

OTHER SOURCE(S) : MARPAT 137:6181

GI



AB Title compds. [I; L, K = O, S; M = N, CH; Y = CH, N; Z = H, (substituted) alkyl; T = N, CH, CR3; R1 = QX; X = (hetero)aryl; Q = bond, O, NR10, S, CO, CO2, NR10CO, NR10CO2, (substituted) alkylene, alkenylene, bivalent alkoxy, alkylthio, alkylamino, aminoalkyl, alkylsulfonyl, alkylsulfonamide, acyl, alkoxy carbonyl; R1R3 = fused carbocyclyl, heterocyclyl; R3 = halo, (substituted) alkyl, alkenyl, alkynyl, NO2, cyano, OR8, NR8R9, CO2R8, COR8, CONR8R9, NR8COR9, NR8CO2R9, OC(O)R8, OC(O)NR8R9, SR8, SOqR8a, NR8SO2Rg, SO2NR5Rq, aryl, heteroaryl, heterocyclo, cycloalkyl, O; 2 adjacent R3 form a (substituted) carbocyclic or heterocyclic fused ring; R4a, R4b = H, halo, (substituted) alkyl, alkenyl, alkynyl, NO2, cyano, OH, alkoxy, alkoxy, PhO, PhCH2O, CO2H, CHO, amino, CO2A, COA, alkylthio; A = alkyl; R8, R9 = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl; R8R9 = atoms to form a heterocyclic ring; R8a = (substituted) alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo; R10 = H, (substituted) alkyl; Q1 = (CH2)s; Q2 = (CH2)r; n, s = 0, 1, 2; q = 1, 2, 3; r = 1, 2; with provisos], were prep'd. as inhibitors of leukointegrin/ICAM assoc'd. conditions (no data). Thus, a mixt. of (7aS,6R)-2-(3,5-dichlorophenyl)-6-hydroxytetrahydropyrrolo[1,2-c]imidazole-1,3-dione (prepn. given), Ph3P, and 4-bromophenol in THF at 0.degree. was treated with diisopropyl azodicarboxylate (DIAD) in THF followed by warming to room temp. overnight to give (7aS,6S)-2-(3,5-dichlorophenyl)-6-(4-bromophenoxy)tetrahydropyrrol o[1,2-c]imidazole-1,3-dione.

IT 433289-16-8P, (7AS,6S)-2-(3,5-dichlorophenyl)-6-(4-bromophenoxy)tetrahydropyrrolo[1,2-c]imidazole-1,3-dione  
433289-20-4P 433289-21-5P 433289-22-6P  
433289-25-9P, (7AS,6S)-2-(3,5-dichlorophenyl)-6-(4-

10000389

bromobenzoyloxy)tetrahydropyrrolo[1,2-c]imidazole-1,3-dione  
**433289-27-1P**, (6S,7AS)-6-(4-bromobenzoyloxy)-2-(3,5-dichlorophenyl)tetrahydropyrrolo[1,2-c]imidazole-1,3-dione  
**433289-28-2P** **433289-29-3P** **433289-30-6P**  
**433289-31-7P** **433289-32-8P** **433289-33-9P**  
**433289-34-0P** **433289-38-4P** **433289-39-5P**  
**433289-40-8P** **433289-41-9P** **433289-42-0P**  
**433289-43-1P** **433289-44-2P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of fused hydantoins as antiinflammatories)

RN 433289-16-8 CAPPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-(4-bromophenoxy)-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-20-4 CAPPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433289-21-5 CAPPLUS

CN Acetamide, N-[(4-cyanophenyl)methyl]-N-[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 433289-22-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-7a(5H)-acetic acid, 6-[(4-cyanophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-, methyl ester, (6R,7aS)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 433289-25-9 CAPLUS

CN Benzoic acid, 4-bromo-, (6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433289-27-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

10000389


Absolute stereochemistry.



RN 433289-28-2 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-(phenylmethoxy)-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-29-3 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[[(4-bromophenyl)methyl]thio]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433289-30-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10000389




RN 433289-31-7 CAPLUS  
CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433289-32-8 CAPLUS  
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(3-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-33-9 CAPLUS  
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10000389




RN 433289-34-0 CAPLUS  
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-(7-isoquinolinylmethoxy)-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433289-38-4 CAPLUS  
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[[(4-bromophenyl)methyl]methylamino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-39-5 CAPLUS  
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[2-(4-bromophenyl)ethyl]amino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

10000389


Absolute stereochemistry.



RN 433289-40-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[3-(4-bromophenyl)propyl]amino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-41-9 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]ethylamino]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433289-42-0 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]propylamino]methyl] - (9CI) (CA INDEX NAME)

10000389


Absolute stereochemistry.



RN 433289-43-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-7a-methyl-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-44-2 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-7a-(hydroxymethyl)-, (6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10000389

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2002:90045 CAPLUS  
DOCUMENT NUMBER: 136:151436  
TITLE: Preparation of combinatorial libraries of  
N-arylsulfonyl-N-diazadioxobicyclooctyl amino acid  
amides as drugs  
INVENTOR(S): Lu, Shao-Po; Hebert, R. Normand  
PATENT ASSIGNEE(S): Lion Bioscience A.-G., Germany  
SOURCE: PCT Int. Appl., 128 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008227	A2	20020131	WO 2001-EP8322	20010718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1301512	A2	20030416	EP 2001-960516	20010718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2000-621177	A 20000721
			WO 2001-EP8322	W 20010718

OTHER SOURCE(S): MARPAT 136:151436  
AB RZN(SO2R1)CHR2CONH2 [I; R = (un)substituted Ph or CH<sub>2</sub>Ph; R<sub>1</sub> =  
2-methoxycarbonyl-3-thienyl, substituted Ph, etc.; R<sub>2</sub> = amino acid side  
chain; Z = 1,3-diaza-2,4-dioxobicyclo[3.3.0]octane-3,6-diyl] were prep'd.  
Data for antibacterial activity of I were given.  
IT 393876-35-2P 393876-37-4P 393876-39-6P  
393876-44-3P 393876-46-5P 393876-47-6P  
393876-54-5P 393876-55-6P 393876-56-7P  
393876-57-8P 393876-61-4P 393876-62-5P  
393876-65-8P 393876-67-0P 393876-68-1P  
393876-72-7P 393876-75-0P 393876-76-1P  
393876-79-4P 393876-80-7P 393876-81-8P  
393876-82-9P 393876-83-0P 393876-84-1P  
393876-85-2P 393876-89-6P 393876-90-9P  
393876-91-0P 393876-92-1P 393876-93-2P  
393876-94-3P 393876-95-4P 393876-96-5P  
393876-97-6P 393877-00-4P  
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study);  
PREP (Preparation); USES (Uses)  
(prep'n. of combinatorial libraries of N-arylsulfonyl-N-  
diazadioxobicyclooctyl amino acid amides as drugs)  
RN 393876-35-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-  
(phenylmethyl)ethyl][(6S,7aS)-2-(3-fluorophenyl)hexahydro-1,3-dioxo-1H-  
pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA)

10000389

INDEX NAME)


Absolute stereochemistry.



RN 393876-37-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-39-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-hexahydro-1,3-dioxo-2-phenyl-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-44-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-chlorophenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-46-5 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-47-6 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[(3-fluorophenyl)sulfonyl][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 393876-54-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-hexahydro-2-(4-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10000389



RN 393876-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-hexahydro-2-(3-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-57-8 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(2,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-61-4 CAPLUS

CN Benzenepropanamide, .alpha.-[[[(6S,7aS)-hexahydro-1,3-dioxo-2-(2,4,5-trimethylphenyl)-1H-pyrrolo[1,2-c]imidazol-6-yl][[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-62-5 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[(6S,7aS)-2-(2-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-65-8 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-67-0 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[[(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-68-1 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[[(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-72-7 CAPLUS

CN Benzenepropanamide, 4-chloro-.alpha.-[[[4-chlorophenyl)sulfonyl][(6S,7aS)-2-(4-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-75-0 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[[4-bromophenyl)sulfonyl][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10000389



RN 393876-76-1 CAPLUS  
CN 1H-Imidazole-4-propanamide, .alpha.-[[[(6S,7aS)-2-(4-biphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-79-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-80-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-81-8 CAPLUS

CN Benzene propanamide, .alpha.-[(6S,7aS)-2-(3-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl](2-thienylsulfonyl)amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10000389

RN 393876-82-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1*S*)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6*S*,7*aS*)-2-(2-fluorophenyl)hexahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-83-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1*S*)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6*S*,7*aS*)-2-(3-chlorophenyl)hexahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-84-1 CAPLUS

CN 1*H*-Imidazole-4-propanamide, .*alpha*.-[(4-bromophenyl)sulfonyl][(6*S*,7*aS*)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.*alpha*.*S*).- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-85-2 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl](2-thienylsulfonyl)amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-89-6 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[[(6S,7aS)-2-(3,5-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-90-9 CAPLUS

CN Benzene propanamide, .alpha.-[[[(6S,7aS)-2-(5-fluoro-2-methylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-91-0 CAPLUS

CN Benzene propanamide, .alpha.-[[[(6S,7aS)-2-(2,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-92-1 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[*(6S,7aS)-2-(2,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl*] [*(3-fluorophenyl)sulfonyl*]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-93-2 CAPLUS

CN Benzenepropanamide, .alpha.-[[*(6S,7aS)-2-[4-(dimethylamino)phenyl]hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl*] [*[4-(trifluoromethyl)phenyl]sulfonyl*]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-94-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-hexahydro-2-[4-(1-methylethyl)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-95-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2,6-difluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-96-5 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3,4-difluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-97-6 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393877-00-4 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[[(3-fluorophenyl)sulfonyl][(6S,7aS)-hexahydro-2-[2-methyl-6-(1-methylethyl)phenyl]-1,3-dioxo-1H-pyrazolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:319894 CAPLUS

DOCUMENT NUMBER: 134:326532

TITLE: Preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of .alpha.1.beta.2 mediated cell adhesion  
INVENTOR(S): Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall; Smith, Nicholas; Griffith, Ronald C.

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.


KIND DATE

APPLICATION NO. DATE

10000389

-----  
WO 2001030781 A2 20010503 WO 2000-US29273 20001019  
WO 2001030781 A3 20011122  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
BR 2000014651 A 20020618 BR 2000-14651 20001019  
JP 2003512468 T2 20030402 JP 2001-533134 20001019  
EP 1307455 A2 20030507 EP 2000-976625 20001019  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL  
PRIORITY APPLN. INFO.: US 1999-160629P P 19991020  
US 2000-209847P P 20000607  
WO 2000-US29273 W 20001019

OTHER SOURCE(S): MARPAT 134:326532  
GI



AB Title compds. (I) [wherein A = :CZ1 or :N; B = CH:CH, S, SO, SO2, O, or (un)substituted N or CH2; K = CH2, CHO, CO, or CF2, M = a bond, (CH2)p, CO, or NH; W = CQ, CR6C(:Q), or C(:Q)CR6; X and Y = independently H, halo, NO2, CN, alkylthio, (halo)alkyl, alkoxy, acyl, or (un)substituted amino or (hetero)aryl; Z and Z1 = independently H, OH, halo, NO2, CF3, acyl, (un)substituted amino, carbamoyl, or alkoxy; P and Q = independently O or S; R = (un)substituted (hetero)aryl; R6 = H or (un)substituted alkyl; m = 0-3; n = 0-2; p and q = independently 1 or 2; or a pharmaceutically acceptable salt thereof] were prep'd. as inhibitors of .alpha.1.beta.2 mediated cell adhesion. For example, 4-bromobenzyl bromide was added to N-(tert-butoxycarbonyl)proline Me ester in THF, the proline deprotected using TFA, 3,5-dichlorophenyl isocyanate added in the presence of DIEA in THF, and the dichlorophenylcarbamoyl deriv. cyclized using NaOEt in ETOH to afford II. In the Jurkat/ICAM-1 adhesion assay, I gave IC50 values from low nM to .mu.M. I are useful in the treatment of a variety of inflammatory diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, atopic dermatitis, Sjogren's Syndrome, rejection after transplantation, and graft vs. host disease (no data).  
IT 336812-89-6P 336812-90-9P 336812-91-0P

10000389


336812-92-1P 336812-93-2P 336816-67-2P  
336816-69-4P 336816-71-8P 336816-73-0P  
336816-77-4P 336816-81-0P 336817-14-2P  
336817-20-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of .alpha.1.beta.2 mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]proline derivs.)

RN 336812-89-6 CAPLUS

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-90-9 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-91-0 CAPLUS

10000389

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-92-1 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-93-2 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-67-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-71-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-73-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-77-4 CAPLUS

CN 1-Piperazinebutanamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-methyl-.gamma.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-81-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336817-14-2 CAPLUS

CN Morpholine, 4-[[6R,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336817-20-0 CAPLUS

CN Morpholine, 4-[[6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10000389

